On November 20, 2024, the final list of winners for the Delaware EDGE (Encouraging Development, Growth & Expansion) competition was announced, with Lisen Imprint among the honorees. The EDGE Award is granted to only 10 businesses per cycle, recognizing the most outstanding and innovative enterprises in Delaware.

                                          Medal of EDGE Award                                   Delaware Governor John Carney presented the award to the founder of Lisen Imprint                                                    

The EDGE Award was established by the Delaware state government in 2019 to encourage technological innovation. When launching the EDGE program, Governor John Carney stated that the award was designed to empower innovative companies, helping them compete against industry giants in a highly competitive market.

As of today, only 110 companies out of the 84,675 small and medium-sized businesses in Delaware have received this honor. Lisen Imprint's recognition not only affirms the company's innovation potential but also serves as encouragement for its continued development of groundbreaking medical products.

During the EDGE Award evaluation process, Lisen Imprint’s proprietary Quantitative Chromogenic Imprinted Gene In Situ Hybridization (QCIGISH) technology received high praise from the Delaware state government.

This technology enables direct visualization and quantitative analysis of the earliest imprinted gene biomarkers in tumors. By integrating artificial intelligence (AI) image recognition and big data statistical models, QCIGISH can sensitively detect malignant tumors at the in situ carcinoma stage—before metastasis occurs. This breakthrough not only allows patients to receive timely treatment but also significantly improves cancer survival rates.

Currently, the accuracy of QCIGISH technology has been validated in over 10,000 tumor samples. Based on this technology, Lisen Imprint has successfully developed early detection products for thyroid cancer, lung cancer, cervical cancer, and other malignancies in China, achieving a sensitivity exceeding 95%.

With the support of the EDGE Award, Lisen Imprint plans to collaborate with Mayo Clinic and other leading U.S. medical institutions to develop an early detection product for melanoma, a rapidly progressing cancer with poor prognosis. This product will assist physicians in distinguishing early in situ melanomas from benign moles, improving preoperative detection rates and enabling early diagnosis and treatment.

Lisen Imprint aims to use its early melanoma detection product as a breakthrough to actively expand into the U.S. and European markets, marking a significant step in its global expansion. At the same time, Lisen Imprint looks forward to collaborating with more medical institutions and research teams to advance the application of imprinted gene tumor biomarkers in early cancer diagnosis, ultimately providing better healthcare solutions for cancer patients worldwide.